CD276 and neoplasm: This may also be a consequence of B7-H3’s two-headed role in immunology as B7-H3 exerts immune-stimulating or immune-suppressing properties depending on the tumor type.18 In 2008, Hashiguchi et al. described TLT-2, triggering receptor expressed on myeloid cells (TREM)-like transcript 2 as the first potential receptor of B7-H3.19,20 However, the interaction between B7-H3 and TLT-2 which was not confirmed by other authors cannot explain the mostly published pro-tumorigenic function of B7-H3 as the authors describe an immune-stimulating role of the B7-H3/TLT-2 interaction.21